Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locoregional Recurrence
Conditions
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Trial Timeline
Sep 13, 2022 → Aug 1, 2029
NCT ID
NCT05467891About Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane
Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane is a phase 2 stage product being developed by Novartis for Locoregional Recurrence. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05467891. Target conditions include Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05467891 | Phase 2 | Recruiting |
Competing Products
1 competing product in Locoregional Recurrence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD2936 | AstraZeneca | Phase 2 | 52 |